2-fluoro-4,5-dimethoxy-aniline | 397-75-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluoro-4,5-dimethoxy-aniline
• 英文别名: 2-Fluor-4,5-dimethoxy-anilin；2-Fluoro-4,5-dimethoxyaniline
• CAS: 397-75-1
• 化学式: C₈H₁₀FNO₂
• mdl: MFCD12174785
• 分子量: 171.171
• InChiKey: LDYNLRCFVQFFNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氟-1,2-二甲氧基苯 在 乙醇 、 硝酸 、 铂 作用下， 生成 2-fluoro-4,5-dimethoxy-aniline
  参考文献：
  名称：

  The Monofluorocatechols

  摘要：

  DOI：

  10.1021/jo50003a002

文献信息

• SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES
  申请人：Snow Alan

  公开号：US20090060838A1

  公开（公告）日：2009-03-05

  Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and diagnosis of amyloid and synuclein diseases.

  本发明提供了取代的n-芳基苯甲酰胺、相关化合物及其药学上可接受的盐、它们的合成和标记、含有它们的制药组合物以及它们在治疗淀粉样疾病中的应用，包括Aβ淀粉样蛋白病，如阿尔茨海默病，IAPP淀粉样蛋白病，如2型糖尿病，以及突触蛋白病，如帕金森病，并制造用于此类治疗的药物。本发明还提供了所述化合物作为成像剂的应用以及体内成像和诊断淀粉样和突触蛋白疾病的方法。
• NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP3904331A1

  公开（公告）日：2021-11-03

  Provided is a novel nanoparticle, a contrast agent for magnetic resonance imaging containing the same, and a zwitterionic ligand compound used in production of the nanoparticle. The contrast agent for MRI of the present invention can be suitably used as a contrast agent for MRI in a medical field. The nanoparticle and the zwitterionic ligand compound of the present invention are applicable to various pharmaceutical compositions and the like, including a contrast agent for MRI, and can be used widely in the fields of pharmaceuticals, biotechnology, and the like, including various diagnosis methods and examination reagents.

  本发明提供了一种新型纳米粒子、一种含有该纳米粒子的磁共振成像造影剂以及一种用于生产该纳米粒子的齐聚物配体化合物。本发明的磁共振成像造影剂可适当用作医疗领域的磁共振成像造影剂。本发明的纳米粒子和齐聚物配体化合物适用于包括核磁共振成像造影剂在内的各种药物组合物等，可广泛应用于医药、生物技术等领域，包括各种诊断方法和检查试剂。
• METHOD FOR PRODUCING NANOPARTICLES INCLUDING METAL PARTICLES CONTAINING IRON OXIDE HAVING AT LEAST ONE HYDROPHILIC LIGAND COORDINATED THERETO
  申请人：Astellas Pharma Inc.

  公开号：EP3904294A1

  公开（公告）日：2021-11-03

  [Problem] A novel method for producing a nanoparticle having a metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded is provided, where the nanoparticle is useful as a contrast agent for magnetic resonance imaging. [Means for Solution] As the novel method for producing a nanoparticle having a metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded, by performing ligand exchange to a hydrophilic ligand from an iron oxide nanoparticle having a surface to which a hydrophobic ligand is coordination bonded in one step using a phase transfer catalyst, it is possible to expect shortening of production processs and reduction of hydrophilic ligands used. Furthermore, by producing an iron oxide nanoparticle having a surface to which a hydrophobic ligand is coordination bonded using a dropwise addition method, it is possible to avoid a rapid temperature rise and a reaction at a high temperature of 200°C or higher, which is more advantageous for industrial production.

  问题 本发明提供了一种生产纳米粒子的新方法，该纳米粒子具有含有氧化铁的金属粒子，在该金属粒子上配位结合了一个或多个亲水配体，该纳米粒子可用作磁共振成像的造影剂。 [解决方法］ 作为生产具有金属颗粒的纳米粒子的新方法，该金属颗粒含有与一个或多个亲水配体配位结合的氧化铁，通过使用相转移催化剂在一个步骤中从具有与疏水配体配位结合的表面的氧化铁纳米粒子与亲水配体进行配体交换，可望缩短生产过程并减少亲水配体的使用。 此外，通过使用滴加法生产具有疏水配体配位键表面的氧化铁纳米粒子，可以避免快速升温和在 200°C 或更高温度下进行反应，这对工业生产更为有利。
• Glutarimides
  申请人：ROHM AND HAAS COMPANY

  公开号：EP0415642B1

  公开（公告）日：1995-12-06
• BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
  申请人：SCHERING CORPORATION

  公开号：EP1453836B1

  公开（公告）日：2007-03-28